STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[6-K] SMITH & NEPHEW PLC Current Report (Foreign Issuer)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
6-K
Rhea-AI Filing Summary

Smith & Nephew plc reported routine share acquisitions by its CEO and senior executives under the Company’s Dividend Re‑Investment Plan. The purchases followed the 2025 interim dividend and were executed on 7 November 2025 on the London Stock Exchange (XLON) at £12.4048 per share.

Participants included Chief Executive Officer Deepak Nath (2,624.43651 shares), President, Sports Medicine Scott Schaffner (746.79305), President, Advanced Wound Management and Global Commercial Operations Rohit Kashyap (427.09066), President, Orthopaedics Craig Gaffin (197.25944), Chief Quality & Regulatory Affairs Officer Mizanu Kebede (4.1729), and President, Global Operations Paul Connolly (394.41542).

The transactions relate to ordinary shares of USD 0.20 each (ISIN: GB0009223206) and were disclosed under UK Market Abuse Regulation.

Positive
  • None.
Negative
  • None.
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
Form 6-K
 
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 under the
Securities Exchange Act of 1934
 
November 10, 2025
 
Commission File Number 001-14978
 
SMITH & NEPHEW plc
(Registrant’s name)
 
Building 5, Croxley Park, Hatters Lane
Watford, England, WD18 8YE
 (Address of principal executive office)
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
 
Form 20-F           Form 40-F __
 
 
SMITH & NEPHEW PLC
 
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
 
This announcement is made in accordance with the UK Market Abuse Regulation (Regulation (EU) 596/2014, as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018).
 
Reason for the notification
 
Initial notification /Amendment
Initial notification
 
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
Name
Smith & Nephew plc
 
LEI
213800ZTMDN8S67S1H61
 
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
 
Description of the financial instrument, type of instrument
 
Smith & Nephew plc ordinary shares of USD 0.20 each
 
Identification code
ISIN: GB0009223206
 
Nature of the transaction
Purchase of ordinary shares through the Company's Dividend Re-Investment Plan following the 2025 interim dividend payment on 7 November 2025.
 
Date of Transaction
2025 - 11 - 07
 
Place of Transaction
London Stock Exchange (XLON)
 
 
 
Name
(Position)
Director / PDMR
 
Price (£)
 
Volume
 
Aggregated information
 
Scott Schaffner
(President, Sports Medicine)
 
PDMR
 
12.4048
 
746.79305
 
N/A Single Transaction
 
Deepak Nath
(Chief Executive Officer)
 
Director
 
12.4048
 
2624.43651
N/A Single Transaction
 
Rohit Kashyap (President, Advanced Wound Management and Global Commercial Operations)
 
PDMR
 
12.4048
 
427.09066
N/A Single Transaction
 
Craig Gaffin
(President, Orthopaedics)
 
PDMR
 
12.4048
197.25944
N/A Single Transaction
 
Mizanu Kebede
(Chief Quality & Regulatory Affairs Officer)
 
PDMR
 
12.4048
4.1729
N/A Single Transaction
 
Paul Connolly
(President, Global Operations)
 
PDMR
 
12.4048
394.41542
N/A Single Transaction
 
  
Philip Horner
Deputy Company Secretary
Smith & Nephew plc
 
Tel:  +44 (0)1923 477100
 
LEI:    213800ZTMDN8S67S1H61
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
 
 
 
 
Smith & Nephew plc
 
 
(Registrant)
 
 
 
 
 
 
Date: November 10, 2025
By:
/s/ Helen Barraclough
 
 
Helen Barraclough
 
 
Company Secretary

FAQ

What did SNN disclose in this Form 6-K?

Smith & Nephew plc disclosed PDMR and director purchases of ordinary shares via the Company’s Dividend Re‑Investment Plan following the 2025 interim dividend.

When were the Smith & Nephew (SNN) PDMR transactions executed?

All reported transactions took place on 7 November 2025.

At what price were the SNN DRIP shares acquired?

Each acquisition was executed at £12.4048 per share.

Which SNN executives participated and what were their volumes?

Examples include Deepak Nath 2,624.43651 shares and Scott Schaffner 746.79305 shares, with additional PDMRs listed.

Where were the SNN transactions conducted?

The transactions were executed on the London Stock Exchange (XLON).

What class of SNN security was involved?

Ordinary shares of USD 0.20 each, ISIN GB0009223206.

Under which regulation were these SNN transactions disclosed?

They were notified under the UK Market Abuse Regulation.
Smith & Nephew

NYSE:SNN

SNN Rankings

SNN Latest News

SNN Latest SEC Filings

SNN Stock Data

14.09B
426.68M
0.03%
7.8%
0.6%
Medical Devices
Healthcare
Link
United Kingdom
Watford